Tempramed reviews 2025, outlines 2026 plans

Executive Summary

• Tempramed Technologies provides a comprehensive recap of 2025 and strategic outlook for 2026, highlighting significant commercial expansion, product innovation, and successful public listing.
• The company completed a public listing in November 2025, raising $7.4 million via an oversubscribed offering on the Canadian Securities Exchange and Frankfurt Stock Exchange.
• Key operational milestones include the launch of the VIVI Cap Smart device, expansion of global distribution partnerships, and the announcement of a new manufacturing facility in Florida to reduce costs and increase output.

Key Details

• Financing: In November 2025, Tempramed went public on the Canadian Securities Exchange (ticker: VIVI) and the Frankfurt Stock Exchange (ticker: 9DY), raising $7.4 million in an oversubscribed offering to accelerate growth and global expansion.
• Product Launch: Launched the VIVI Cap Smart device, an advanced evolution of the flagship VIVI Cap that integrates digital health functionality with passive temperature-protection technology. This addition enables real-time data tracking for compliance and efficacy and introduces a subscription-based business model via a connected mobile application.
• Distribution Partnerships:
  • Entered an exclusive distribution partnership with Guri AAO in Israel.
  • Signed a commercial distribution agreement with a leading Turkish health care distributor.
  • Expanded presence in Western Europe (Netherlands, Belgium, Luxembourg).
  • Secured a strategic agreement with Maccabi Health Care Services, Israel's second-largest HMO serving over 2.8 million members.
• Manufacturing: Announced a new manufacturing facility in Florida, USA, in December 2025, aimed at increasing output, reducing cost of goods sold (COGS), and enhancing service for B2B customers.
• Intellectual Property: Granted an additional patent in South Korea, expanding protection for core thermal-regulation technology.
• Scientific Advisory: Appointed Prof. Lutz Heinemann, a leader in diabetes research and insulin pharmacology, to the scientific advisory board.
• 2026 Strategic Focus:
  • Accelerating market penetration in North America, Europe, the Middle East, and Asia.
  • Advancing next-generation product development for the VIVI platform.
  • Deepening relationships with HMOs, insurers, and pharmaceutical partners to achieve insurance reimbursement.
  • Expanding clinical and patient education initiatives.

Notable Quotes

• Ron Nagar, CEO: "Two thousand twenty-five represented an important year of execution and validation for Tempramed. As the company moves into 2026, the focus remains on expanding access to its life-saving technology while continuing to innovate at the intersection of science, patient needs and global health care systems... We are transforming a major industry and next year will be even more exciting than this one."
• Ilan Cohen, Chairman: "I am extremely happy with the progress Tempramed made in 2025, from operational efficiencies to distribution and partnership expansion, as well as completing a public listing... Two thousand twenty-six will be a strong year for the company as we continue to expand and unlock commercialization opportunities globally."